Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064211%3A_____%2F14%3A%230000299" target="_blank" >RIV/00064211:_____/14:#0000299 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.thromres.2013.11.002" target="_blank" >http://dx.doi.org/10.1016/j.thromres.2013.11.002</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.thromres.2013.11.002" target="_blank" >10.1016/j.thromres.2013.11.002</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec

Popis výsledku v původním jazyce

In the treatment of bleeds in haemophilia patients with inhibitors,a high initial dose of recombinant Factor VIIa (rFVIIa) provides at least equal efficacy and a similar safety profile to a standard initial dose. However, no pharmacoeconomic comparison between these dosing regimens has previously been performed. Here, we assess the pharmacoeconomics of high (>120 &#956;g/kg) versus standard (&#8804;120 &#956;g/kg) initial rFVIIa dose in inhibitor patients and the impact of time to treatment initiation on costs and outcomes.In a retrospective analysis, observational data on bleed characteristics, rFVIIa treatment, hospitalizations and outcomes were extracted from the Czech Republic HemoRec registry. Crude comparisons and generalized linear regression modelling (GLM; correcting for patient differences) were performed to compare costs and outcomes between the high and standard initial dosing groups.

Název v anglickém jazyce

Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec

Popis výsledku anglicky

In the treatment of bleeds in haemophilia patients with inhibitors,a high initial dose of recombinant Factor VIIa (rFVIIa) provides at least equal efficacy and a similar safety profile to a standard initial dose. However, no pharmacoeconomic comparison between these dosing regimens has previously been performed. Here, we assess the pharmacoeconomics of high (>120 &#956;g/kg) versus standard (&#8804;120 &#956;g/kg) initial rFVIIa dose in inhibitor patients and the impact of time to treatment initiation on costs and outcomes.In a retrospective analysis, observational data on bleed characteristics, rFVIIa treatment, hospitalizations and outcomes were extracted from the Czech Republic HemoRec registry. Crude comparisons and generalized linear regression modelling (GLM; correcting for patient differences) were performed to compare costs and outcomes between the high and standard initial dosing groups.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FJ - Chirurgie včetně transplantologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Thrombosis research

ISSN

0049-3848

e-ISSN

—

Svazek periodika

133

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

162-167

Kód UT WoS článku

000329572600007

EID výsledku v databázi Scopus

—